GlassScriptPhysician profile
Annette Li
NPI 1801201322
$1,947.57
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $112 · 2021: $289 · 2022: $643 · 2023: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $298.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $604.41 | 2019 | |
| Gilead Sciences, INC. | $203.98 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.83 | 2022-2023 | Jardiance, Synjardy, Trijardy Xr |
| Novo Nordisk INC | $164.89 | 2021-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $159.58 | 2022-2023 | Farxiga, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $133.39 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $107.95 | 2022 | |
| Welch Allyn | $88.41 | 2021 | |
| Corium, LLC | $63.85 | 2022-2023 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.02 | 2022-2023 | Xifaxan, Trulance |
| Baxter Healthcare | $53.04 | 2022 | |
| Lilly USA, LLC | $48.58 | 2022-2023 | Mounjaro |
| Abbott Laboratories | $20.17 | 2022 | |
| Glaxosmithkline, LLC. | $15.97 | 2022 | |
| Ibsa Pharma INC. | $12.55 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $11.99 | 2022 | |
| Amgen INC. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.